Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…

If all baby boomers got tested for hep C, that could help stem freefall of Gilead's blockbusters—and it's exactly the move the company is…

This year’s flu vaccine is working for almost half of recipients, the CDC says in an update on what it’s calling a “moderate” season.

J&J is the most admired pharma company, according to Fortune's annual corporate poll, for the fourth year in a row and comes in at No. 13 among all…

Pfizer scored new Crohn’s data that could give its Remicade biosimilar, Inflectra, more oomph for its market-share fight, one of the first U.S. head-to-heads…

AbbVie’s former blockbuster AndroGel faces a class-action lawsuit over side effects—and a trial of a different sort as new testosterone-replacement data paint…

Ahead of the Supreme Court’s hearing in Amgen v. Sandoz “patent dance” case, biosimilars advocates are criticizing a lower court's 'detrimental…

Celgene’s late-stage pill, ozanimod, could hit $2b in sales and add pressure to an already competitive oral MS market, analysts say.

AstraZeneca snagged $250 million-plus for its cancer drug Zoladex in the U.S., where it brought in only $69 million last year. The deal, AZ's latest slim-…